Trials / Unknown
UnknownNCT00525577
ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study
AGI-1067 as a Novel Antidiabetic Agent Evaluation Study
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 1,012 (estimated)
- Sponsor
- AtheroGenics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This double-blind, placebo-controlled, dose-finding study is designed to identify the lowest AGI-1067 dose that improves glycemic control as measured by HbA1c and fasting glucose in subjects with Type 2 diabetes mellitus. Glycemic control will be measured during a 6-month treatment period in subjects who are on 1 or no antidiabetic drugs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo tablet, once daily |
| DRUG | AGI-1067 | 75 mg AGI-1067 tablet, once daily |
| DRUG | AGI-1067 | 150 mg AGI-1067 Tablet, once daily |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-06-01
- Completion
- 2008-09-01
- First posted
- 2007-09-06
- Last updated
- 2008-02-06
Locations
90 sites across 8 countries: United States, Bosnia and Herzegovina, Georgia, India, North Macedonia, Serbia and Montenegro, South Africa, Ukraine
Source: ClinicalTrials.gov record NCT00525577. Inclusion in this directory is not an endorsement.